Arthritis Research & Therapy

CORRECTION

Open Access

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Martin Bergman[1], Namita Tundia[2], Naomi Martin[2], Jessica L. Suboticki[2], Jayeshkumar Patel[2], Debbie Goldschmidt[3], Yan Song[3*] and Grace C. Wright[4]

Correction: Arthritis Res Ther 24, 155 (2022) https://doi.org/10.1186/s13075-022-02813-x

Following publication of the original article [1], the authors reported an error in Additional files 1 and 2 as the axes on the supplemental figures were unclear. The additional files were updated.

The original article [1] has been updated.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02940-5.

Additional file 1: Figure S1. Proportion of Patients Reporting PRO Scores ≥ Normative Values at Baseline and weeks 12 and 24. [a]ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg). ABA, abatacept; BL, baseline; EQ-5D-5L (index score), EQ-5D 5-Level; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire Disability Index; IV, intravenous; LDA, low disease activity; MCS, Mental Component Summary; PCS, Physical Component Summary; PRO, patient-reported outcome; PtGA, Patient Global Assessment of Disease Activity; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib. **P*<0.05 for UPA vs ABA. †*P*=0.05 for UPA vs ABA.

Additional file 2: Figure S2. Proportion of Patients Reporting SF-36 Scores ≥ Normative Values at Baseline and weeks 12 and 24. [a]ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg). ABA, abatacept; BL, baseline; BP, bodily pain; GH, general health; IV, intravenous; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib; VT, vitality. **P*<0.05 for UPA vs ABA.

The original article can be found online at https://doi.org/10.1186/s13075-022-02813-x.

*Correspondence: Yan.Song@analysisgroup.com

[3] Analysis Group, Inc, Boston, MA, USA
Full list of author information is available at the end of the article

Author details
[1]Drexel University College of Medicine, Philadelphia, PA, USA. [2]AbbVie Inc, North Chicago, IL, USA. [3]Analysis Group, Inc, Boston, MA, USA. [4]Grace C Wright MD PC; Association of Women in Rheumatology; United Rheumatology, New York, NY, USA.

Published online: 03 November 2022

Reference

1. Bergman M, Tundia N, Martin N, et al. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther. 2022;24:155. https://doi.org/10.1186/s13075-022-02813-x.